Rockefeller Capital Management
CTMX icon

Rockefeller Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Rockefeller Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,864
Closed -$2K – 2381
2022
Q4 		$2K Sell
1,864
-485
-21% -$718 ﹤0.01% 3551
2022
Q3 		$3K Hold
2,349
– – ﹤0.01% 3468
2022
Q2 		$4K Hold
2,349
– – ﹤0.01% 3520
2022
Q1 		$6K Hold
2,349
– – ﹤0.01% 3265
2021
Q4 		$10K Hold
2,349
– – ﹤0.01% 2971
2021
Q3 		$11K Hold
2,349
– – ﹤0.01% 2839
2021
Q2 		$14K Hold
2,349
– – ﹤0.01% 2631
2021
Q1 		$18K Hold
2,349
– – ﹤0.01% 2322
2020
Q4 		$15K Hold
2,349
– – ﹤0.01% 2108
2020
Q3 		$15K Buy
+2,349
New +$17.4K ﹤0.01% 1879

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rockefeller Capital Management's CTMX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of CytomX Therapeutics (CTMX) in Q1 2023, closing a stake of 1,864 shares — an estimated $2K sold.

Rockefeller Capital Management first reported a position in CTMX in Q3 2020 and held it in 10 quarters. The position peaked at $18K in Q1 2021. 75 funds tracked by Wall St. Rank hold CTMX as of Q1 2023.

  • Rockefeller Capital Management reported no remaining CytomX Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 1,864 CytomX Therapeutics shares in Q1 2023, an estimated $2K.
  • Rockefeller Capital Management first reported a position in CytomX Therapeutics in Q3 2020 and held it in 10 quarters.
  • Rockefeller Capital Management's CytomX Therapeutics position peaked at $18K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.